Investors Urged to Contact Robbins LLP Over Medpace Holdings Losses

Law firm investigates allegations that Medpace misled investors about its book-to-bill ratio

Apr. 14, 2026 at 10:05pm

Got story updates? Submit your updates here. ›

A highly detailed, black-and-white close-up image of complex banking machinery and equipment, conveying a sense of the institutional power and security of the financial industry without using literal currency or charts.An extreme close-up of the intricate inner workings of the financial industry highlights the importance of transparency and accountability for public companies.San Diego Today

Robbins LLP has filed a class action lawsuit on behalf of investors who purchased Medpace Holdings Inc. (NASDAQ: MEDP) securities between April 22, 2025 and February 9, 2026. The lawsuit alleges that Medpace, a clinical contract research organization, misled investors about its expected book-to-bill ratio during this period.

Why it matters

The lawsuit claims Medpace provided overly optimistic guidance about its book-to-bill ratio, a key metric for CROs, throughout 2025. When the company announced a lower-than-expected ratio in Q4 2025, its stock price dropped significantly, causing losses for investors.

The details

According to the complaint, Medpace continuously told investors to expect a book-to-bill ratio of 1.15 during the second half of fiscal year 2025. However, on February 9, 2026, the company reported a Q4 2025 book-to-bill ratio of only 1.04, well below the guidance. This news caused Medpace's stock price to fall more than 15.9% in a single day.

  • The class period is from April 22, 2025 to February 9, 2026.
  • Medpace announced its Q4 2025 book-to-bill ratio of 1.04 on February 9, 2026.
  • Medpace's stock price fell from $530.35 per share on February 9, 2026 to $446.05 per share on February 10, 2026.

The players

Robbins LLP

A law firm that has filed a class action lawsuit against Medpace Holdings Inc. on behalf of investors who suffered losses.

Medpace Holdings Inc.

A clinical contract research organization (CRO) that is accused of misleading investors about its expected book-to-bill ratio.

Got photos? Submit your photos here. ›

What’s next

Shareholders who wish to serve as lead plaintiff for the class must submit their papers to the court by June 8, 2026.

The takeaway

This case highlights the importance of accurate financial guidance from public companies, especially for key metrics like book-to-bill ratio that are closely watched by investors in the CRO industry. The lawsuit alleges Medpace provided overly optimistic projections that ultimately did not materialize, leading to significant losses for shareholders.